342 related articles for article (PubMed ID: 26699621)
1. Stable Human Hepatoma Cell Lines for Efficient Regulated Expression of Nucleoside/Nucleotide Analog Resistant and Vaccine Escape Hepatitis B Virus Variants and Woolly Monkey Hepatitis B Virus.
Cheng X; Guan W; Sun S; Li B; Li H; Kang F; Kang J; Yang D; Nassal M; Sun D
PLoS One; 2015; 10(12):e0145746. PubMed ID: 26699621
[TBL] [Abstract][Full Text] [Related]
2. Generation of a human hepatoma cell line supporting efficient replication of a lamivudine resistant hepatitis B virus.
Zhang Y; Zhang Y; Kang Y; Wang J; Liu H; Zhu H; Qin Y; Mao R; Lin X; Lu M; Zhang J
J Virol Methods; 2014 Jun; 201():51-6. PubMed ID: 24583110
[TBL] [Abstract][Full Text] [Related]
3. Characterization of novel human hepatoma cell lines with stable hepatitis B virus secretion for evaluating new compounds against lamivudine- and penciclovir-resistant virus.
Fu L; Cheng YC
Antimicrob Agents Chemother; 2000 Dec; 44(12):3402-7. PubMed ID: 11083647
[TBL] [Abstract][Full Text] [Related]
4. Novel stable HBV producing cell line systems for expression and screening antiviral inhibitor of hepatitis B virus in human hepatoma cell line.
Ogura N; Ogawa K; Watashi K; Ito T; Wakita T
Biochem Biophys Res Commun; 2018 Mar; 498(1):64-71. PubMed ID: 29481805
[TBL] [Abstract][Full Text] [Related]
5. Stable HepG2- and Huh7-based human hepatoma cell lines for efficient regulated expression of infectious hepatitis B virus.
Sun D; Nassal M
J Hepatol; 2006 Nov; 45(5):636-45. PubMed ID: 16935386
[TBL] [Abstract][Full Text] [Related]
6. Trends in hepatitis B virus resistance to nucleoside/nucleotide analogues in North China from 2009-2016: A retrospective study.
Guo X; Wu J; Wei F; Ouyang Y; Li Q; Liu K; Wang Y; Zhang Y; Chen D
Int J Antimicrob Agents; 2018 Aug; 52(2):201-209. PubMed ID: 29654894
[TBL] [Abstract][Full Text] [Related]
7. In vitro characterization of the anti-hepatitis B virus activity and cross-resistance profile of 2',3'-dideoxy-3'-fluoroguanosine.
Jacquard AC; Brunelle MN; Pichoud C; Durantel D; Carrouée-Durantel S; Trepo C; Zoulim F
Antimicrob Agents Chemother; 2006 Mar; 50(3):955-61. PubMed ID: 16495257
[TBL] [Abstract][Full Text] [Related]
8. Treatment of chronic hepatitis B: Evolution over two decades.
Yuen MF; Lai CL
J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():138-43. PubMed ID: 21199525
[TBL] [Abstract][Full Text] [Related]
9. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks.
Yang H; Westland CE; Delaney WE; Heathcote EJ; Ho V; Fry J; Brosgart C; Gibbs CS; Miller MD; Xiong S
Hepatology; 2002 Aug; 36(2):464-73. PubMed ID: 12143057
[TBL] [Abstract][Full Text] [Related]
10. Anti-HBV drugs suppress the growth of HBV-related hepatoma cells via down-regulation of hepatitis B virus X protein.
Zhang S; Gao S; Zhao M; Liu Y; Bu Y; Jiang Q; Zhao Q; Ye L; Zhang X
Cancer Lett; 2017 Apr; 392():94-104. PubMed ID: 28192212
[TBL] [Abstract][Full Text] [Related]
11. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro.
Chen RY; Edwards R; Shaw T; Colledge D; Delaney WE; Isom H; Bowden S; Desmond P; Locarnini SA
Hepatology; 2003 Jan; 37(1):27-35. PubMed ID: 12500185
[TBL] [Abstract][Full Text] [Related]
12. The main hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non-nucleoside inhibitors of HBV replication.
Billioud G; Pichoud C; Puerstinger G; Neyts J; Zoulim F
Antiviral Res; 2011 Nov; 92(2):271-6. PubMed ID: 21871497
[TBL] [Abstract][Full Text] [Related]
13. Naturally occurring hepatitis B virus (HBV) variants with primary resistance to antiviral therapy and S-mutants with potential primary resistance to adefovir in Argentina.
Cuestas ML; Rivero CW; Minassian ML; Castillo AI; Gentile EA; Trinks J; León L; Daleoso G; Frider B; Lezama C; Galoppo M; Giacove G; Mathet VL; Oubiña JR
Antiviral Res; 2010 Jul; 87(1):74-7. PubMed ID: 20403388
[TBL] [Abstract][Full Text] [Related]
14. [Determination of reverse transcriptase inhibitor nucleoside analogue resistance profile in pretreatment phase of patients with viral hepatitis B].
Öksüz Z; Serin MS; Serin A; Sezgin O; Gonca S
Mikrobiyol Bul; 2019 Apr; 53(2):156-169. PubMed ID: 31130120
[TBL] [Abstract][Full Text] [Related]
15. Comparison of replication competence of wild-type and lamivudine-resistant hepatitis B virus isolates from a chronic hepatitis B patient.
Zhang Q; Chen J; Pan M; Liu J; Liu T; Zhou YH
Virus Res; 2018 Aug; 255():165-170. PubMed ID: 30075160
[TBL] [Abstract][Full Text] [Related]
16. Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains.
Amini-Bavil-Olyaee S; Herbers U; Luedde T; Trautwein C; Tacke F
J Viral Hepat; 2011 Nov; 18(11):804-14. PubMed ID: 20887378
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis B virus: from diagnosis to treatment.
Dény P; Zoulim F
Pathol Biol (Paris); 2010 Aug; 58(4):245-53. PubMed ID: 20580167
[TBL] [Abstract][Full Text] [Related]
18. Virological response and hepatocarcinogenesis in lamivudine-resistant hepatitis B virus genotype C patients treated with lamivudine plus adefovir dipivoxil.
Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
Intervirology; 2008; 51(6):385-93. PubMed ID: 19229115
[TBL] [Abstract][Full Text] [Related]
19. Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance.
Papatheodoridis GV; Dimou E; Papadimitropoulos V
Am J Gastroenterol; 2002 Jul; 97(7):1618-28. PubMed ID: 12135009
[TBL] [Abstract][Full Text] [Related]
20. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]